

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Cormorant Asset Management, LP</u> (Last) (First) (Middle) <u>200 CLARENDON STREET, 52ND FLOOR</u> (Street) <u>BOSTON MA 02116</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Kiniksa Pharmaceuticals, Ltd. [KNSA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/29/2018</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Common Shares ("Common Shares")	05/29/2018		C		830,999	A	(1)	830,999	I	See Footnote ⁽²⁾⁽³⁾
Common Shares	05/29/2018		P		69,444	A	\$18	900,443	I	See Footnotes ⁽²⁾⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Series C Preferred Shares	(1)	05/29/2018		C			830,999	(1)	(1)	Common Shares	830,999	(1)	0	D ⁽²⁾⁽³⁾

1. Name and Address of Reporting Person* <u>Cormorant Asset Management, LP</u> (Last) (First) (Middle) <u>200 CLARENDON STREET, 52ND FLOOR</u> (Street) <u>BOSTON MA 02116</u> (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person*		
<u>Chen Bihua</u>		
(Last)	(First)	(Middle)
C/O CORMORANT ASSET MANAGEMENT, LLC		
100 HIGH STREET, SUITE 1103		
(Street)		
BOSTON	MA	02110
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
<u>Cormorant Global Healthcare GP, LLC</u>		
(Last)	(First)	(Middle)
100 HIGH STREET		
1 FEDERAL STREET		
(Street)		
BOSTON	MA	02110
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
<u>Cormorant Global Healthcare Master Fund, LP</u>		
(Last)	(First)	(Middle)
100 HIGH STREET		
SUITE 1105		
(Street)		
BOSTON	DC	02110
(City) (State) (Zip)		

Explanation of Responses:

1. The Series C Preferred Shares were convertible at any time, at the holder's election, on a 1-for-2.73235 basis and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.
2. Shares reported herein are held by Cormorant Private Healthcare Fund I, LP (the "Fund I"), Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and by a managed account (the "Account"). Cormorant Asset Management, LLC ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
3. Shares reported herein represent (i) 640,617 Common Shares held by Fund I, (ii) 161,962 Common Shares held by the Master Fund, and (iii) 28,420 Common Shares held by the Account.
4. Shares reported as purchased herein on May 29, 2018 represents (i) 60,291 shares purchased by the Master Fund, and (ii) 9,153 shares purchased by the Account.

/s/ CORMORANT GLOBAL HEALTHCARE GP, LLC By: Bihua 05/31/2018

/s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC its General Partner, By: Bihua Chen, Managing Member 05/31/2018

/s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP By: Cormorant Global Healthcare GP, LLC, its General Partner By: Bihua Chen, Managing Member 05/31/2018

/s/ Bihua Chen 05/31/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.